Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA Target Action Date Set May 1, 2027

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.